Purpose: HHLA2 (B7H7/B7-H5/B7y) is a newly identified B7 family member that regulates human T cell functions. However, its protein expression in human organs and significance in human diseases are unknown. The objective of this study was to analyze HHLA2 protein expression in normal human tissues and cancers, its prognostic significance, to explore mechanisms regulating HHLA2 expression, and to identify candidate HHLA2 receptors.
pathway represents a novel immunosuppressive mechanism within the tumor microenvironment and an attractive target for human cancer therapy.
Translational relevance:
The B7 and CD28 families are critical in regulating T cell responses and antibodies against PD-1, PD-L1 and CTLA-4 have successfully led to durable clinical remissions in various malignancies. HHLA2 was recently discovered as a new member of the B7 family and shown to regulate T cell function. Here we showed that HHLA2 had limited expression in normal human tissues but was expressed in various human cancers. We demonstrated its expression on tumor cells was associated with increased lymph node metastases in limited stage triple negative breast cancer (TNBC). Analyzing the TCGA database revealed TNBC had higher HHLA2 copy number gains than other subtypes of breast cancer, providing a mechanism of overexpression.
Finally, we identified one of the receptors for HHLA2. This is the first study to report HHLA2 expression in human cancers and clinical significance, and together with its previously reported T cell co-inhibition properties show that this could contribute to tumor immune suppression and be a target for cancer immunotherapy.
Introduction
The past decade has witnessed an important change in the understanding of T cell biology and tumor immunology with the recognition of immune checkpoints through the B7-CD28 pathways (1-3). B7-1/B7-2/CD28/CTLA-4 is the prototypic B7/CD28 pathway. This loop of costimulation and coinhibition is critical for regulating the early stages of T cell responses in lymphoid organs. Several additional B7 family members are believed to play important roles in peripheral tolerance and tumor immune evasion-PD-L1 [B7-H1 (4,5)], B7-H3 (6) and B7x [B7-H4/B7S1 (7) (8) (9) ]. The ligands PD-L1, B7-H3 and B7x function by inhibiting effector T cells in peripheral tissues (10, 11) . These ligands are expressed in various human cancers and their expression can lead to immune tolerance in the tumor microenvironment by inhibiting T cell proliferation and function (1, (12) (13) (14) . In addition, B7x can interact with myeloid-derived suppressor cells (15, 16) , which may also promote tumor growth. Clinically, higher expression of these ligands is associated with a poor prognosis in various malignancies. Based on these functional and clinical observations, blocking some of the B7-CD28 pathways has yielded some therapeutic success in human malignancies. The anti-CTLA-4 antibody achieved clinical responses in melanoma (17) while anti-PD-L1 or anti-PD-1 antibodies have shown responses in melanoma, renal cell cancer, and non-small cell lung cancer (18) (19) (20) . The therapeutic responses seen in these patients are durable and they are longer than chemotherapy or other targeted agents.
HERV-H LTR-associating 2 (HHLA2, also called B7H7/B7-H5/B7y) has been recently discovered as the newest member of the B7 family (21) (22) (23) and has 23-33% similarity in amino acid sequence with the other B7 molecules (21) . This ligand is the only B7 family member that is found in humans but not in mice. It is constitutively expressed on the surface of human monocytes and is induced on B cells. HHLA2 binds to its putative receptor(s) on a variety of 
Methods

Patients and Samples
Normal and cancerous tissue microarrays were purchased from Imgenex Corp for the analysis of HHLA2 expression in human tissues. For the TNBC cohort 50 cases were selected from our tumor registry between 2002 -2011 who were diagnosed with local or locally advanced breast cancer diagnosed at our institution between 2002-2011. All of these patients underwent surgery as the primary treatment followed by chemotherapy or radiotherapy or both. Tissue blocks from the mastectomy or lumpectomy specimen were located and slides were made from the same section. This was done so as to enable us to determine whether HHLA2 expression in the primary tissue is associated with prognostic features. Using retrospective chart review, the relevant clinical data were collected from the files. Hormone receptor status and Her2 status were also obtained by retrospective review. All protocols were reviewed and approved by the Institutional Review Board.
Monoclonal Antibodies and Immunohistochemistry
A mouse monoclonal antibody against HHLA2 (Clone 566.1, IgG1) and 3T3 cell lines expressing HHLA2 or CTLA-4 were recently generated (21) . Cell blocks of the 3T3 cells expressing either HHLA2 or CTLA-4 were prepared for IHC controls by fixing the cells with 4% paraformaldehyde and then embedding them in HistoGel (Thermo Scientific). These samples were then embedded in paraffin and cut onto slides and used as positive and negative controls, respectively. These controls were then stained for HHLA2 using our mAb. Briefly, 4 to 5 µm thick formalin fixed paraffin embedded specimens slides were used. The tissue sections were deparaffinized in xylene and dehydrated through graded alcohols to water. The samples were boiled in citrate buffer (pH 6.0) using a microwave for 2 minutes and then incubated in an antigen retrieval steam chamber between 80-100°C for 30 minutes. To block endogenous peroxidase activity all of the sections were treated with 3% hydrogen peroxide for 10 min.
Nonspecific binding of IgG was blocked by using serum-free protein block solution (Dako). The sections were incubated with anti-HHLA2 mAbs for 30 minutes. They were then incubated with Dako envision+ HRP-labeled anti-mouse polymer. Signals were generated by incubation with 3, 3'-diaminobenzidine. Finally the sections were counterstained with hematoxylin and observed under the microscope. The slides were reviewed in tandem by a breast pathologist and by an oncology physician trained in breast pathology.
Cell Lines and FACS
Cell lines were cultured in either complete RPMI or DMEM. Cells were stained with anti-HHLA2 mAb 566.1 and then with a secondary anti-mouse IgG-APC conjugated antibody. 
Bioinformatic Analysis
The NCBI database was queried for proteins of the immunoglobulin family with homologues in humans and monkeys, but not in mice or rats. The sequences of the resulting list of proteins were analyzed by various domain-prediction programs to determine if these proteins contained Ig, IgC, IgC-like, IgV, or IgV-like domains. The list was further refined by excluding proteins that did not contain a transmembrane domain. MacVector 10.6. was used for sequence alignment and homology comparison. The phylogenetic tree was generated by PAUP (4.0b10) after removal of significant inserts and trimming C-and N-terminal extensions from sequence alignments (24) . Motifs and domains were analyzed with EMBL-EBI tools, SMART, and CBS Prediction. For gene copy number variations, the cBioPortal for Cancer Genomics database and the Cancer Genome Atlas were analyzed.
Fusion Protein Production and Purification
TMIGD2-Ig fusion protein was prepared by PCR-amplifying the extracellular domain of the protein without the signal peptide. The amplified product was inserted into a human IgG1 Fc tag of plasmid pMT/BiP as described previously (7) . Drosophila Schneider 2 cells were cotransfected with this construct and a plasmid inducing hygromycin resistance. The fusion protein was expressed in Express Five serum-free medium (Life Technologies) and purified using Protein G Plus Agarose columns (Pierce). The purity of the fusion protein was confirmed by SDS-PAGE.
Statistical Analysis
For continuous variables t-test was used when the normality assumption was met and the rank sum test and median was calculated for those, which violated normality. Chi-squared test was used to analyze the association between categorical variables and if the expected frequency is less than 5 in more than 20% of the cells, Fisher's exact test was used. All p values <0.05 was considered statistically significant.
Results
Normal human tissue expression of HHLA2
The expression of HHLA2 protein in human tissues is unknown at present. To examine the protein expression, we used our recently-generated HHLA2-specific monoclonal antibody clone 566.1 to develop an immunohistochemistry protocol to detect HHLA2 in formalin fixed paraffin-embedded specimens in which 3T3 cells expressing HHLA2 or CTLA-4 served as positive and negative controls, respectively ( Figure S1 ). We used this technique to stain tissue microarrays of normal human organs (Table 1) . Our results demonstrated that the majority of normal organs did not express HHLA2 at the protein level; however, trophoblastic cells of the placenta and epithelial cells of the gut, kidney, gallbladder and breast expressed this ligand ( Figure 1 and Table 1 ). While primary and secondary lymphoid organs were largely negative, a few scattered cells appeared to stain positively in these samples. These results reveal that 
HHLA2 is widely expressed in various human cancers
HHLA2 is able to inhibit both human CD4 and CD8 T cell functions (21), therefore it is possible that human cancer may exploit this pathway as an immune evasion mechanism. As no knowledge currently exists about HHLA2 protein in human cancer tissues, we next examined the expression of HHLA2 in human cancer tissues using immunohistochemical staining of tissue microarrays of common cancers from various organs (Figure 2 ). HHLA2 was expressed in 50% or more of cancer samples from the breast (7 of 10), lung (6 of 9), thyroid (6 of 9), melanoma (5 of 9), ovary (4 of 8), and pancreas (5 of 10) ( Table 2 ). The localization of the protein was membranous and cytoplasmic in tumor cells (Figure 2 ). HHLA2 protein was also expressed in cancers of the liver, bladder, colon, prostate, kidney, and esophagus (Table 2 and Figure 2 ). In addition, we found that of the 20 human cell lines examined in breast cancer and hematological malignancies of leukemia and lymphoma, 12 expressed HHLA2 on their surface by flow cytometry (Table S1 ). These results demonstrate that HHLA2 protein is widely over-expressed in human cancers and has a high prevalence in certain malignancies.
HHLA2 expression in triple negative breast cancer
We also evaluated HHLA2 expression in a cohort of 50 patients with early stage triple negative breast cancer (TNBC) because of the limited therapeutic options for this breast cancer subtype. The characteristics of the patient population are shown in Using immunohistochemical staining we found that within a given TNBC tumor, the expression and intensity of HHLA2 protein was quite homogeneous throughout the tumor.
Hence HHLA2 expression was graded based on intensity of staining between 0 and 3. Grades of 0 and 1 had no or minimal staining, respectively, whereas 2 and 3 had moderate and strong membranous/cytoplasmic staining. 0 and 1 were considered to be negative or low expression while 2 and 3 were considered to be high expression (Figure 3 ).
In the 50 TNBC samples stained, HHLA2 was graded as 0 in 12% (n = 6), 1 in 32% (n = 16), 2 in 40% (n = 20) and 3 in 16% (n = 8) of the tissue sections (Table 3) . When classified as a binary variable, 56% (n = 28) exhibited high (grades 2 or 3) and 44% (n = 22) had low expression (grades 0 or 1) of HHLA2. In the bivariate analysis, high HHLA2 expression was associated with lymph node positivity (0 vs. ≥1, p = 0.04) and advanced stage of the disease (p = 0.03) at the time of diagnosis, features known to be associated with an increased risk of recurrence. HHLA2 expression was not related to age or to the size of the tumor. Together, these data demonstrate that more than half of TNBC tumors have HHLA2 overexpression and that patients with higher levels of HHLA2 on their tumors are significantly more likely to have the disease spread and at an advanced stage.
HHLA2 gene copy number variations in triple negative breast cancer
Research. HHLA2 was overexpressed at the protein level in breast cancer, but the mechanism(s) upregulating the expression in cancer cells is unknown. Therefore we sought to determine whether gene amplification was a potential mechanism of overexpression. By analyzing the cBioPortal for Cancer Genomics database (25, 26) , we found that HHLA2 gene alterations were present in 18.8% and 23% of all cases with breast cancer in The Cancer Genome Atlas (TCGA) (27) and in the TCGA provisional database studies, respectively. Since TNBC is predominantly comprised of the basal subtype, we compared the copy number gain of the HHLA2 locus in basal vs. non basal breast cancer using the TCGA registry. HHLA2 was altered in 32% of the basal subtype which is almost twice the frequency observed in all breast cancers independent of their subtype (18%). The vast majority of HHLA2 copy number variations (CNVs) in basal breast cancers were amplifications or gains (>95%). Hence, given that HHLA2 protein up-regulation is present in approximately 56% of our samples, our results suggest that one mechanism of up regulation of HHLA2 protein in TNBCs is gene copy number gain.
Identification of transmembrane and immunoglobulin domain-containing protein 2 (TMIGD2) as one of the receptors for HHLA2
Receptors for HHLA2 are widely expressed on both naïve and activated T cells as well as dendritic cells, monocytes, and B cells (21) . As HHLA2 is a member of the immunoglobulin superfamily and has orthologs in humans and monkeys but not in mice or rats, we hypothesized the receptors for HHLA2 may belong to the immunoglobulin superfamily and have the same phylogenetic pattern due to co-evolution. ( Figure 4A) . By sequence analysis, we found TMIGD2, the immunoglobulin-containing and proline-rich receptor-1 (IGPR-1)(30), and CD28 homologue (CD28H) (22) are the same molecule. IGPR-1 was originally identified as a adhesion molecule involved in angiogenesis (30) , while CD28H was recently reported as a receptor by a high-throughput screen of transmembrane proteins (22) . Thus TMIGD2/IGPR-1/CD28H is one of the receptors for HHLA2.
Discussion
The B7 ligand family and the CD28 receptor family are the major driving force of T cell costimulation and coinhibition. These molecules have been intensely studied for their potential clinical impact in human malignancies, especially with regards to ectopic tumor cell expression of negative coinhibitory molecules. Here we present the first study on the protein expression, 
clinical significance, and mechanism of up-regulation of HHLA2 in human tissues and cancers.
The results reveal that HHLA2 is a suitable target for cancer therapy. another B7 family member, was recently shown to protect against gut inflammation in mouse models (31) . Future investigation is warranted to determine whether HHLA2 in the intestines contributes to the immune tolerance or intestinal inflammation. We observed high expression of HHLA2 in the placental tissue, suggesting it may play a role in fetal maternal immune tolerance.
Interestingly, HHLA2 polymorphisms are associated with Autism spectrum disorders, a disease whose etiology remains poorly understood (32) . Immune dysregulation was recently proposed to contribute to the rapid development of Autism spectrum disorder in genetically susceptible children (32) . Further study will also be required to determine whether HHLA2 is involved in the development of Autism spectrum disorder. Images were acquired at 10x. A summary of staining results from tissue microarrays is shown in Table 1 . 
